Using Mendelian randomization study to assess the renal effects of antihypertensive drugs.

ABSTRACT:

Background

Angiotensin-converting enzyme (ACE) inhibitors and/or in combination with calcium channel blockers (CCBs) are generally recommended as the first-line antihypertensive therapy for people with hypertension and kidney dysfunction. Evidence from large randomized controlled trials comprehensively comparing renal effects of different classes of antihypertensive drugs is lacking.

Methods

We used a Mendelian randomization study to obtain unconfounded associations of genetic proxies for antihypertensives with kidney function. Specifically, we used published genetic variants in genes regulating target proteins of these drugs and then applied to a meta-analysis of the largest available genome-wide association studies of kidney function (estimated glomerular filtration rate (

SUBMITTER: Zhao JV 

PROVIDER: S-EPMC7995783 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature